Document is current
Any future updates will be listed below
-
Authors
Pignolo, Robert J. https://orcid.org/0000-0002-8533-9438
Hsiao, Edward C.
Baujat, Genevieve
Lapidus, David
Sherman, Adam
Kaplan, Frederick S.
-
Funding
Funding for this research was provided by:
Ipsen Biopharmaceuticals
Regeneron Pharmaceuticals
Perelman School of Medicine, University of Pennsylvania
National Institutes of Health (NIH R01AR073015)
University of California, San Francisco
Radiant Hope Foundation
Mayo Clinic (Robert and Arlene Kogod Professorship)
- License Information
-
More Information
Article History
Received: 21 February 2021
Accepted: 25 July 2021
First Online: 5 August 2021
Declarations
:
: All data collection followed HIPPA and local Institutional Review Board regulations.
: This manuscript contains no individual person’s data in any form.
: None of the authors have competing interests to report. Robert J. Pignolo: Research investigator: Clementia/Ipsen, Regeneron; Advisory board: President of the International Clinical Council on FOP. Edward C. Hsiao: Research Investigator, Clementia/Ipsen; Prior research support from Regeneron. And Neurocrine Biosciences. Volunteer service on the IFOPA Medical Registry Advisory Board, the Fibrous Dysplasia Foundation Medical Advisory Board, and the International Clinical Council (ICC) of FOP. Genevieve Baujat: Research Investigator Ipsen, Regeneron, member of the International Clinical Council (ICC) of FOP, European Council for FOP and FOP France Medical Advisory Board. David Lapidus: David Ladipus was paid as a consultant by IFOPA for his work in compiling data. Prior consultant for Clementia (role ended in September, 2019). Adam Sherman: None. Frederick S. Kaplan: Research investigator: Ipsen & Regeneron; IFOPA Medical Advisory Board; Founder and Immediate Past-President of the International Clinical Council (ICC) on FOP; Chair of the Publications Committee of the ICC.
